Latest news - Novo Nordisk
Dec 15, 2024 · We plan to invest 2.9 billion Danish kroner to establish a cutting-edge quality control laboratory in Hillerød, Denmark. Environmental challenges have never been more critical or more urgent than they are today. But at Novo Nordisk, we never allow complexity to become a barrier to change.
Novo Nordisk shares plunge on the back of disappointing
6 days ago · Novo Nordisk shares have plunged 20% amid the disappointing trial result of its latest weight-loss drug CagriSema. The fall wiped out €90bn in market valuation on Friday.
Novo Nordisk A/S: CagriSema demonstrates superior weight
Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and ...
Novo Nordisk shares tumble as data on weight-loss drug trial …
Dec 20, 2024 · Novo Nordisk and Eli Lilly are competing for dominance in a market that grew sevenfold in just three years to $24bn in 2023, according to data analytics firm Iqvia.
Compounded semaglutide associated with at least 10 deaths, Novo Nordisk …
Nov 6, 2024 · Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have been associated with at least 100 hospitalizations and 10 deaths, the chief...
Novo Nordisk Shares Plunge After New Obesity Shot Disappoints
Novo Nordisk ’s big bet to improve on the success of its weight-loss drug franchise hit a stumbling block Friday, wiping out nearly $100 billion of the drugmaker’s stock-market value.
US FDA approves Novo Nordisk's bleeding disorder drug
Dec 20 (Reuters) - The U.S. Food and Drug Administration has approved Novo Nordisk's (NOVOb.CO), opens new tab drug for the prevention or reduction of bleeding episodes in patients with a type of ...
News Details - novonordisk.com
Oct 21, 2024 · Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial Bagsværd, Denmark, 21 October 2024 — Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial.
Company announcements & press releases - Novo Nordisk
Be the first to read our company announcements and press releases. Our medicines are for the approved indication for which they are authorised in the local country or region. For more information, please visit our product page.
Novo Nordisk’s next-generation weight-loss drug CagriSema
Dec 20, 2024 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in late ...